10 Hot Stocks to Watch — Monday, August 10, 2026

Moderna rallied sharply after Q2 earnings revealed a 5% net-loss improvement driven by international partnerships and manufacturing efficiencies, while management reaffirmed 2026 growth targets despite tightened cost guidance. The biotech is advancing flu, oncology, and rare-disease programs toward key milestones, and just initiated a Phase 1 trial for a Bundibugyo Ebola vaccine—expanding its infectious-disease portfolio amid a $13.3B global flu-vaccine market by 2030. Options traders are aggressively bullish: a 6.14 call/put ratio and heavy call volume across $58–$64 strikes expiring August 14 signal conviction; watch $62 resistance as the next technical hurdle.

SoundHound AI fell 8.65% today despite Thursday's 26% surge on better-than-expected Q2 earnings and raised FY26 guidance. The pullback comes as analysts reassess valuations: DA Davidson maintained Buy but cut its price target to $10, while Piper Sandler downgraded to Neutral at $7. Options markets remain aggressively bullish with an 8.47 call-to-put ratio and heavy volume in $8 and $10 strikes through mid-August, suggesting traders still view $10 as near-term support despite analyst caution.

ServiceNow surged 6.42% to $124.88 today after unveiling six new Autonomous Security solutions designed to detect and remediate threats preemptively—cementing its position in a rapidly expanding cybersecurity segment. Options traders are betting on continuation, with a lopsided 10.29 call-to-put ratio and heavy volume in $130 calls expiring mid-to-late August, suggesting conviction above current levels. Watch the $130 strike as near-term resistance; a close above it could trigger acceleration toward the 52-week high of $194.73.

Coinbase jumped 5.6% to $153.60 today, reclaiming ground as Bitcoin stabilized above $65,000 despite regulatory headwinds. The options market is flashing conviction: call-to-put ratio stands at 4.69 with heavy accumulation in $155–$165 strike calls expiring August 14, suggesting traders are positioning for a move toward resistance. However, a Michigan court rejection of Coinbase's enforcement bid and Senate delays on the Clarity Act keep regulatory uncertainty elevated; watch whether the stock can hold above the 52-week low of $139.18.

Qualcomm rallied 4.66% to $167.86, extending gains as the chip designer's strategic shift toward data center and automotive markets resonates with options traders. A torrent of call buying—led by 6,717 contracts at the $175 September strike and a 7.96 call-to-put ratio—signals conviction that the handset slowdown won't derail earnings growth. Watch $175 as the key breakout level; sustained momentum above it could fuel a run toward the 52-week high of $259.92.

GameStop climbed 2.93% to $22.15 after eliminating $1.4 billion in convertible debt via stock swap—a move that preserves cash as the retailer pursues its eBay partnership strategy. Options traders are piling into calls, with a 4.82 call-to-put ratio and heavy volume in $19.50 and $20 August 14 contracts signaling conviction on near-term upside. Watch the $28.10 resistance level, which marks the 52-week high and a potential breakout point if sentiment sustains.

Robinhood jumped 2.84% to $93.29 on Friday after forming its first Golden Cross in 2.5 years, signaling potential long-term momentum. The broker's record Q2 profitability—with platform assets surging past $369 billion—and strategic crypto push, including a new $200M venture fund launching Aug. 13, bolster the technical setup. Options traders are heavily long, with call volume spiking 13,716 contracts at the $100 strike (expiring Aug. 14), while the 1.91 call-put ratio confirms sustained bullish conviction. Watch $100 resistance as the key breakout level.

Tesla climbed 2.83% to $328.58, settling near the upper band of its recent range as bullish options flow intensified. Call-to-put ratio of 1.66 signals sustained demand, with heavy positioning in $325–$330 strikes expiring August 2026, suggesting traders expect further upside. The stock trades 34% below its 52-week high of $498.83, leaving room for mean reversion if near-term momentum holds above current support near $327.50.

BioNTech fell after missing Q2 revenue by $59M and slashing full-year sales guidance to $1.86B–$2.21B from $2.33B–$2.68B, citing collapsing COVID vaccine demand. The biotech named new CEO Guido Oelkers amid the pivot toward oncology, yet Citigroup and Evercore both trimmed price targets despite maintaining buy ratings. Options markets are screaming caution: heavy put buying has pushed the C/P ratio to 0.00, with $70 and $97.50 puts drawing 246x and 155x volume respectively, signaling traders are hedging downside risk through at least Q1 2027.